

Chrono Therapeutics Announces Appointment of David Happel as Chief Executive Officer

Dr. Alan Levy to Retire as CEO

Hayward, CA – February 1, 2018 – Chrono Therapeutics, a pioneer in digital drug therapy, today announced that Alan Levy Ph.D., Chief Executive Officer (CEO) and Chairman of the Board of Directors is retiring. David A. Happel has been appointed as the new CEO and current Board member James Young will assume the role of Chairman of the Board. Dr. Levy will continue to serve as a member of the Board.

“I’m very pleased with the progress we have made over the last four years, including the excellent clinical results in our smoking cessation application as well the progress we have made on our Parkinson’s and opioid-tapering programs that target important unmet clinical needs.” said Dr. Levy. “With Dave’s background and experience in both the biotech and pharmaceutical industries – and his focus on commercialization – he is the ideal person to take the company through its next chapter.”

“It is an honor to succeed Alan and I am very excited to build on the foundation that has been created at Chrono Therapeutics as the company continues to advance its proprietary SmartDermal therapeutics and technology platform into the later stages of clinical development and commercialization,” stated Mr. Happel.

Mr. Happel joins Chrono Therapeutics from Horizon Pharma, PLC where he was Executive Vice President of Commercial Development and Strategy. During his tenure at Horizon, Mr. Happel was responsible for the commercialization of Horizon’s five marketed orphan disease products and the development of Horizon’s rare disease pipeline portfolio. Prior to Horizon Pharma, he was the Chief Commercial Officer of Raptor Pharmaceuticals where he had worldwide responsibility for the commercialization of Raptor’s two marketed orphan disease products and the development of Raptor’s pipeline portfolio. Previously, Mr. Happel also held senior management positions at Allergan Research Corporation, Dynavax Technologies, Dr. Reddy’s Laboratories, Chiron Corporation and Intermune. Mr. Happel received his B.A. in Chemistry from Indiana University and his M.B.A in Marketing from Indiana State University.

“On behalf of the entire Board, we thank Alan for his endless dedication and commitment to the company over the last four years. Under his leadership Chrono Therapeutics has built a rich pipeline of product candidates to address unmet needs in addictions and central nervous systems (CNS) disorders with a vision to improve patient outcomes and lives,” commented James Young, Chairman of the Board.

About Chrono Therapeutics

Chrono Therapeutics is dedicated to improving the lives of patients living with addictions and other neurological conditions by combining smart drug delivery, personalized behavioral support, data analytics, and improved compliance into one integrated product. Chrono Therapeutics’ transdermal drug delivery platform is smarter: providing just the right amount of medication timed to when patients’ symptoms are at their strongest and medication is most needed. With our technology, drug delivery is personalized and has the potential to be significantly more efficacious.

For more information, visit: www.chronothera.com.

For Investor and Public Relations questions, please contact:
Anthony M. Rimal
Chief Financial Officer
Chrono Therapeutics inc.
510-362-0776